Table 2.
Tumor responses for patients with HCC and PVTT in the S-TACE or the A-TACE group.
| Response | Sorafenib + TACE group (n = 32) (cases %) | Apatinib + TACE group (n = 41) (cases %) | P value |
|---|---|---|---|
| Complete response | 1 (3.1) | 1 (2.4) | 0.529 |
| Partial response | 10 (31.3) | 19 (46.3) | |
| Stable disease | 10 (31.3) | 6 (46.3) | |
| Progressive disease | 11 (34.4) | 15 (36.6) | |
| Objective response | 11 (34.4) | 20 (48.7) | |
| Disease control | 21 (65.6) | 26 (63.4) |
HCC, hepatocellular carcinoma; PVTT, portal vein tumor thrombosis; S-TACE, sorafenib-transarterial chemoembolization; A-TACE, apatinib-transarterial chemoembolization.